Revenue

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

A landmark private equity deal in Europe's produce sector is about more than money; it's a strategic move to build a resilient food supply chain.

Beyond the press release: How two strategic hires signal Plus Therapeutics' aggressive push to commercialize its CNSide platform and capture a $6B market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

How the world's largest Catholic media network leveraged its global infrastructure to turn a grassroots prayer event into a worldwide phenomenon.

A Chinese city is investing in a new tourism model, blending adrenaline sports and ancient culture to capture a lucrative youth market. A strategic play.

With a critical $1.74M lifeline, Northstar Clean Technologies is racing to prove its shingle recycling tech can be a profitable circular economy champion.

Granted a tight deadline by Nasdaq, Triller Group must fix its finances and failing stock price or face delisting. Is its hybrid social media-fintech model viable?

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.

The fashion giant beat earnings and initiated a dividend, but declining sales and consumer uncertainty reveal a complex picture for the apparel industry.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

A new initiative empowers local leaders to deploy a data-backed 'catch-up' learning method, aiming to solve Africa's foundational education crisis.

A Pennsylvania health system is partnering with an online platform to fast-track nurses, a model that could be a blueprint for a nation in crisis.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

A deep dive into the valuation impasse that scuttled a major oil merger, and what the fallout means for Parex, GeoPark, and Latin American energy M&A.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

With backing from the US and Australia, a titanium giant is pivoting to critical minerals, a strategic move challenging global supply chain dominance.

The platform's 2025 report reveals more than just charity; it's a real-time indicator of economic distress, disaster response, and tech-driven mutual aid.